CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) — Garuda Therapeutics (Garuda), a biotechnology company creating off-the-shelf, HSC therapies for a multitude of blood disorders, today announced the successful completion of an approximately $50 million Series A-1 funding round. Investors included OrbiMed, Northpond Ventures and Cormorant Asset Management, with new strategic investment from Kyowa Kirin Co., Ltd., a Japan-based Global Specialty Pharmaceutical Company.
This investment underscores the growing need for an immediate, off-the-shelf and cost-effective solution to stem cell transplants. Garuda’s technology enables self-renewing blood stem cells that are durable, human leukocyte antigen (HLA)-compatible, and transgene-free. As the industry’s potential first off-the-shelf offering, Garuda’s technology has the opportunity to address a multitude of unique blood disorders and eliminate dependency on donor blood cells. The Series A-1 funding will support the advancement of …
